Five Prime Therapeutics (FPRX) Misses Q3 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Five Prime Therapeutics Reports Third Quarter 2020 Results
November 3, 2020 4:05 PM ESTTop-Line Phase 2 FIGHT data on track to be announced in 2020 FPT155 advancing to year-end goal of informing next steps for the program Enrollment in the monotherapy exploratory cohort continues at the 560mg dose Enrollment in the dose escalation of FPT155 in combination with pembrolizumab has advanced to the second cohort in patients with non-small cell lung cancer Novel antibody targeting CCR8 moves into IND-enabling studies Year-end cash guidance raised to $100 to $105 million
SOUTH SAN FRANCISCO, Calif.--(BUSINESS... More
